Collaborative mechanisms for sustainable health innovation
The case of vaccines and antibiotics
The provision of key health technologies and products such as vaccines and antibiotics
is insufficient in purely competitive and volume-based markets, requiring new revenue
streams for sustainability. Recent developments in health innovation suggest that
innovative collaborative mechanisms can be effective in addressing this issue. In
the domains of vaccines and antibiotics, these approaches should incorporate shared
research investment, long-term access planning, the provision of manufacturing infrastructure,
supply chains, and financial returns. Collaborative approaches such as subscription
models could be piloted at the regional level, while other models could be developed
to delink innovation, manufacturing, and access from sales volume and revenue. Finally,
blended finance instruments from the development field could encourage greater collaboration
among established and emerging stakeholders in health innovation. These stakeholders
should work together to create, test, access, and implement more collaborative approaches
to health innovation to share upfront investments, mitigate risks of failure, and
accelerate market access.
Available from March 10, 2023
In series:OECD Science, Technology and Industry Policy Papersview more titles